The fibrinolytic system components are increased in systemic sclerois and modulated by Alprostadil (alpha 1 ciclodestryn)

Clinical and Experimental Rheumatology

Volumn 23, Issue 5, 2005, Pages 671-677

  Bandinelli, Francesca ^a   Bartoli, Francesca ^a   Perfetto, Federico ^a   Del Rosso, Angela ^a   Moggi Pignone, Alberto ^a   Guiducci, Serena ^a   Cinelli, Marina ^a   Fatini, Cinzia ^a   Generini, Sergio ^a   Gabrielli, Armando ^b   Giacomelli, Roberto ^c   Bongi, Susanna Maddali ^a   Abbate, Rosanna ^a   Del Rosso, Mario ^a   Cerinic, M Matucci ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Fibrinolysis; Prostaglandins; Systemic sclerosis

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CLEBOPRIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDIN E1; PROTON PUMP INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; FEMALE; FIBRINOLYSIS; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

AGED; ALPROSTADIL; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, CELL SURFACE; SCLERODERMA, SYSTEMIC; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 24944530570     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. KAHALEH B, MEYER O, SCORZA R: The assessment of the patient with systemic sclerosis. Assessment of vascular involvement. Clin Exp Rheumatol 2003; 21: S1-49.
2. AMES: The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome. Br J Rheumatol 1997. 36: 1045-50.
3. LEE P, NORMAN CS, SUKENIK S, ALDERDICE CA: The clinical significance of coagulation abnormalities in systemic sclerosis (scleroderma). J Rheumatol 1985; 12: 514-7.
4. MATUCCI-CERINIC M, VALENTINI G, SORANO GG et al.: Blood coagulation, fibrinolyisis and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 2003; 33: 1-11.
5. CUNLIFFE WJ, MENON IS: Blood fibrinolytic activity in diseases of small blood vessels and the effect of low molecular weight dextran. Br J Dermatol 1969; 81: 220-9.
6. HOLLAND CD, JAYSON MIV: Venous blood fibrinolysis and fibrinolytic potential in primary Raynaud's phenomenon and systemic scleroderma associated Raynaud's phenomenon. In BLACK CM, MYERS AR, (Eds.) Systemic Sclerosis. New York; Gower Medical Publisher Limited, 1985: 267-74
7. BROWSE NI, GRAY L, JARRET PEM et al.: Blood and vein wall fibrinolytic activity in health and in vascular diseases. Br Med J 1977; 1: 478-83.
8. HERRICK AL, ILLINGWORTH K, BLANN A, HAY CRM, HOLLIS S, JAYSON MIV: Von Willebrand factor, thrombomodulin, thromboxane, β-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996; 5: 122-7.
9. MATUCCI-CERINIC M, LOTTI T, LOMBARDI A et al.: Cutaneous and plasma fibrinolytic activity in systemic sclerosis. Evidence of normal plasminogen activation. Int J Dermatol 1990; 29: 644-7.
10. LOTTI T, MATUCCI-CERINIC M, MARMUGI D, FABBRI P: Cutaneous fibrinolytic activity in scleroderma. Clin Exp Rheumatol 1985; 3: 248-51.
11. 1. Ann Intern Med 1999; 130: 412-21.
12. 1 on microvascular haemodynamics in progressive systemic sclerosis. Br Med J 1982; 285: 1688-90.
13. 1. Prostaglandin Leukotrien Essential Fatty Acids 2000; 63: 271-7.
14. 1 alphacyclodextrin improves endothelial cell injury in systemic sclerosis. J Rheumatol 2001; 28: 786-94.
15. SAKSELA O, RIFKIN DB: Cell-associated plasminogen activation: Regulation and physiological functions. Ann Rev Cell Biol 1988; 4: 93-126.
16. Le ROY EC, BLACK C, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
17. STEEN VD, MEDSGER TA Jr: Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001; 44: 2828-35.
18. FURST DE, CLEMENTS PJ, STEEN VD et al.: The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998; 25: 84-8.
19. CUTOLO M, GRASSI W, MATUCCI CERINIC M: Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum 2003; 48: 3023-30.
20. MARASINI B, CUGNO M, BASSANI C, STANZANI M, BOTTASSO B, AGOSTONI A: Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon. Int J Microcirc Clin Exp 1992; 11: 375-82.
21. FALANGA V, KRUSKAL JB, FRANKS JJ: Fibrin and fibrinogen-related antigens in systemic sclerosis (scleroderma). J Am Acad Dermatol 1994; 31: 297-8.
22. KALLENBERG CGM,VELLENGA E, WOUDA AA: Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon. J Rheumatol 1982; 9: 878-84.
23. SICA S, PAOLETTI S, STORTI S, PAGANO L, MARRA R, GARCOVICH A: Il sistema emocoagulativo nella sclerodermia sistemica progressiva. Minerva Med 1987; 78: 1831-4.
24. MUNKVAD S, GRAM J, JESPERSEN J: Depressed plasma fibrinolytic activity in a group of patients with connective tissue diseases. Scand J Rheumatol 1989; 18: 277-82.
25. HAUSTEIN UF, SCHEEL H, SIEGEMUND A, KRUSCHE U: Vascular function parameters in idiopathic and quartz-induced progressive scleroderma. Hautarzt 1993; 44: 717-22.
26. TRIFILETTI A, BARTOLONE S, SCAMARDI R et al.: Evaluation of haemostatic parameters and circadian variations of the haemostatic system in patients with systemic sclerosis and Raynaud's phenomenon. Panminerva Med 2000; 42: 7-9.
27. SILVERI F, DE ANGELIS R, POGGI A et al.: Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis. Scand J Rheumatol 2001; 30: 290-6.
28. 1 in systemic sclerosis. Prog Clin Biol Res 1989; 301: 469-73.
29. 1-cyclodextrin treatment of Raynaud's phenomenon in patients with systemic sclerosis. In: MACHTEY I, (Ed.) Proceedings of the 8th International Seminar on the Treatment of Rheumatic Disease, Dec. 6-12, 1999, Petah-Tiqva, Israel. Progress Rheumatol 1999; 7: 65-70.
30. 1 infusions for vascular insufficiency in progressive systemic sclerosis. Ann Rheum Dis 1981; 40: 350-4.
31. 1 in Raynaud's syndrome. Ann Rheum Dis 1985; 44: 754-60.
32. MARASINI B, CUGNO M, AGOSTONI A: Plasma levels of tissue-type plasminogen activator and von Willebrand factor in patients with Raynaud's phenomenon. Arthritis Rheum 1991; 34: 255-6.
33. GOODFIELD MJ, ORCHARD MA, ROWELL NR: Whole blood platelet aggregation and coagulation factors in patients with systemic sclerosis. Br J Hematol 1993; 84: 675-80.
34. BOGATKEVICH GS, TOURKINA E, SILVER RM, LUDWICKA-BRADLEY: A thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. J Biol Chem 2001; 276: 45184-92.
35. DAWES KE, GRAY AJ, LAURENT GJ: Thrombin stimulates fibroblast chemotaxis and replication. Eur J Cell Biol 1993; 61: 126-30.
36. RIBES JA, FRANCIS CW, WAGNER DD: Fibrin induces release of von Willebrand factor from endothelial cells. J Clin Invest 1987; 79: 117-23.
37. SENIOR RM, SKOGEN WE, GRIFFIN GL, WILNER GDJ: Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B J Clin Invest 1986; 77: 1014-9.
38. 1 restores the levels of vWF and ACE in chronic critical limb ischemia in systemic sclerosis Clin Exp Rheumatol 1999; 1: 358.
39. FERNEBRO E, MADSEN RR, FERNO M et al.: Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients. Eur J Cancer 2001; 37: 486-91.
40. GAO W, WANG Z, BAI X et al.: Detection of soluble urokinase receptor by immunoradiometric assay and its application in tumor patients. Thromb Res 2001; 102: 25-31.
41. MUSTJOKI S, SIDENIUS N, SIER CF et al.: Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res 2000; 60: 7126-32.
42. SIER CF, STEPHENS R, BIZIK J et al.: The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998; 58: 1843-9.
43. STEPHENS RW, PEDERSEN AN, NIELSEN HJ et al.: ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997; 43: 1868-76.
44. SIDENIUS N, SIER CF, ULLUM H et al.: Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000; 96: 4091-5.
45. EUGEN-OLSEN J, GUSTAFSON P, SIDENIUS N et al.: The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 2002; 6: 686-92.
46. FLORQUIN S, van den BERG JG, OLSZYNA DP et al.: Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int 2001; 59: 2054-61.
47. WINKLER F, KASTENBAUER S, KOEDEL U et al.: Role of the urokinase plasminogen activator system in patients with bacterial meningitis. Neurology 2002; 59: 1350-5.
48. RESNATI M, GUTTINGER M, VALCAMONICA S et al.: Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996; 15: 1572-82.
49. ASANO S, SEISHIMA M, KITAJIMA Y: Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line. Clin Exp Dermatol 2001; 26: 289-95.
50. HOYER-HANSEN G, PESSARA U, HOLM A et al.: Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. Biochem J 2001; 358: 673-9.
51. DANO K, ROMER J, NIELSEN BS et al.: Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS 1999; 107: 120-7.
52. WEI Y, LUKASHEV M, SIMON DI et al.: Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-5.
53. CHAPMAN HA, WEI Y: Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb Haemost 2001; 86: 124-9.
54. FAZIOLI F, RESNATI M, SIDENIUS N et al.: A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 1997; 16: 7279-86.
55. RESNATI M, PALLAVICINI I, WANG JM et al.: The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA 2002; 99: 1359-64.
56. CHAVAKIS T, WILLUWEIT AK, LUPU F, PREISSNER KT, KANSE SM: Release of soluble urokinase receptor from vascular cells. Thromb Haemost 2001; 86: 686-93.